ATE144428T1 - Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort - Google Patents

Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort

Info

Publication number
ATE144428T1
ATE144428T1 AT91907902T AT91907902T ATE144428T1 AT E144428 T1 ATE144428 T1 AT E144428T1 AT 91907902 T AT91907902 T AT 91907902T AT 91907902 T AT91907902 T AT 91907902T AT E144428 T1 ATE144428 T1 AT E144428T1
Authority
AT
Austria
Prior art keywords
hydroxyapatite
triggering
poly
immune response
antigen conjugates
Prior art date
Application number
AT91907902T
Other languages
English (en)
Inventor
Jean-Pierre Kraehenbuhl
Helen M Amerongen
Marian R Neutra
Original Assignee
Harvard College
Suisse Rech Experiment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Suisse Rech Experiment filed Critical Harvard College
Application granted granted Critical
Publication of ATE144428T1 publication Critical patent/ATE144428T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT91907902T 1990-04-16 1991-04-16 Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort ATE144428T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/510,154 US5443832A (en) 1990-04-16 1990-04-16 Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response

Publications (1)

Publication Number Publication Date
ATE144428T1 true ATE144428T1 (de) 1996-11-15

Family

ID=24029591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907902T ATE144428T1 (de) 1990-04-16 1991-04-16 Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort

Country Status (16)

Country Link
US (2) US5443832A (de)
EP (1) EP0477339B1 (de)
JP (1) JPH04507106A (de)
KR (1) KR100188836B1 (de)
AT (1) ATE144428T1 (de)
AU (1) AU643011B2 (de)
BG (1) BG60371B1 (de)
BR (1) BR9105718A (de)
CA (1) CA2060318A1 (de)
DE (1) DE69122828T2 (de)
HU (1) HU216103B (de)
OA (1) OA09525A (de)
RO (1) RO109817B1 (de)
RU (1) RU2126270C1 (de)
WO (1) WO1991016072A1 (de)
ZA (1) ZA912838B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
GB2245559A (en) * 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US6290962B1 (en) 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US6290970B1 (en) * 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
AU733712B2 (en) * 1996-06-21 2001-05-24 Synsorb Biotech Inc. Use of oligosaccharides for neutralising E. coli toxins
US8728536B2 (en) * 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
CA2361377C (en) * 1999-02-05 2009-02-03 Alk-Abello A/S Novel mucosal delivery system
DK2116257T3 (da) * 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2006204620B2 (en) * 2000-09-14 2008-05-29 Px Biosolutions Pty Ltd Composition comprising immunogenic nanoparticles
AU2002248289A1 (en) * 2000-10-20 2002-09-04 Etex Corporation Chemotherapeutic composition using calcium phosphate paste
JP5189763B2 (ja) * 2003-04-11 2013-04-24 エテックス コーポレーション 骨誘導性骨材料
JP4982084B2 (ja) * 2004-02-09 2012-07-25 株式会社サンギ 抗腫瘍剤
WO2005100398A1 (ja) * 2004-04-14 2005-10-27 Bio Matrix Research Inc. 抗体ライブラリー作製方法
KR101218454B1 (ko) * 2004-04-15 2013-01-04 에텍스 코포레이션 세팅 지연 칼슘 포스페이트 페이스트
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
JPWO2006038315A1 (ja) * 2004-10-07 2008-07-31 株式会社サンギ 経皮・経粘膜吸収製剤
EP1872798B1 (de) * 2005-04-06 2013-06-05 Kabushiki Kaisha Sangi Intestinales absorptionsfähiges antitumorales mittel
FR2885525B1 (fr) * 2005-05-13 2009-09-18 Urodelia Sa Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue
WO2007053781A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
WO2009081172A1 (en) * 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
GB201319548D0 (en) 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
TWI654993B (zh) * 2016-11-04 2019-04-01 National Health Research Institutes 陽離子型生物可降解性陶瓷聚合物微粒子用以遞送疫苗之用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3599150A (en) * 1969-08-01 1971-08-10 Miles Lab Stabilized aluminum hydroxide suspensions
US4016252A (en) * 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
JPS59101145A (ja) * 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4757017A (en) * 1984-09-14 1988-07-12 Mcw Research Foundation, Inc. In vitro cell culture system
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
JPS62248487A (ja) * 1986-04-22 1987-10-29 Dentaru Kagaku Kk グルカナーゼを固定化したアパタイトおよびその製造法
JPS63196281A (ja) * 1987-02-12 1988-08-15 Sumitomo Electric Ind Ltd 細胞培養用基材
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
CN1057785A (zh) * 1990-04-16 1992-01-15 哈佛大学校长及研究员协会 合成多聚免疫球蛋白受体,受体-抗体复合物,生产及应用
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response

Also Published As

Publication number Publication date
HUT63337A (en) 1993-08-30
BG60371B1 (bg) 1994-11-15
DE69122828D1 (de) 1996-11-28
ZA912838B (en) 1992-03-25
AU7684991A (en) 1991-11-11
WO1991016072A1 (en) 1991-10-31
OA09525A (en) 1992-11-15
US6541000B1 (en) 2003-04-01
BR9105718A (pt) 1992-07-21
HU9200135D0 (en) 1992-04-28
KR920702628A (ko) 1992-10-06
EP0477339A1 (de) 1992-04-01
CA2060318A1 (en) 1991-10-17
KR100188836B1 (ko) 1999-06-01
EP0477339B1 (de) 1996-10-23
RU2126270C1 (ru) 1999-02-20
AU643011B2 (en) 1993-11-04
RO109817B1 (ro) 1995-06-30
DE69122828T2 (de) 1997-05-28
US5443832A (en) 1995-08-22
HU216103B (hu) 1999-04-28
JPH04507106A (ja) 1992-12-10
EP0477339A4 (en) 1993-04-21

Similar Documents

Publication Publication Date Title
ATE144428T1 (de) Hydroxyapatit-antigen-konjugate und verfahren zur auslösung einer poly-ig-immunantwort
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES2011334A6 (es) Metodo para la deteccion de anticuerpos de hiv-2.
ES2086546T3 (es) Productos de cemento de alta duracion conteniendo cenizas siliceas.
EP0306524A4 (de) Von antikörpern, die unter verwendung eines eine beschränkte anzahl von antigenen präsentierenden pathogenen agens oder eines seiner derivate hergestellt worden sind, erkannte antigene determinanten.
GB8423993D0 (en) Pyridine-soluble extract
ZA904174B (en) Monoclonal antibodies for inducing tolerance
DE58906811D1 (de) Verfahren zur Erzeugung eines amplitudenmodulierten ISB-Sendesignals sowie Vorrichtung zur Durchführung des Verfahrens.
DE3785157T2 (de) Verfahren zur herstellung von toxoid.
FI875015A (fi) Vaccin mot juverinflammation.
ES2131308T3 (es) Composiciones y metodos que utilizan el receptor de mpl no ligado para estimular la produccion de plaquetas.
EP0202642A3 (de) Verfahren zur in vitro-Immunisierung von Humanmilzzellen gegen tumorassoziierte Antigene
DE3681036D1 (de) Verfahren und vorrichtung zum einstellen und befestigen eines kuenstlichen beines.
DE68917709T2 (de) Verfahren zur Herstellung eines Pertussis-Toxin-Toxoides.
ATE108664T1 (de) Verfahren zur verhütung von gvhd.
NO914945L (no) Hydroksyapatit-antigenkonjugater og fremgangsmaater for aa frembringe en poly- ig immunreaksjon
AU8417191A (en) Production of and compositions for the major cs1 pilin antigen including vaccines and diagnostic probes
EP0309898A3 (de) Methode zur Induktion einer zytotoxischen T-Zell-Antwort
CS630287A1 (en) Mouse lymphocytar hybridome producing antibodies against"core" antigen of b-hepatitis
MX9205607A (es) Procedimiento para la preparacion de: griseofulvina
PL257646A1 (en) Apparatus for producing pattent fuel of wooden and/or plant wastes
ATE72624T1 (de) Vorrichtung zur erzeugung einer umhuellung von kraftstrahlen.
IE861358L (en) Process for the in vitro immunization of human splenocytes¹against tumor associated antigens
PL265100A2 (en) A method of generating a fuel-air mixture and a means used for its generation and used in conjunction with a carburett or and an air filter
AU1508088A (en) Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties